Michaela Dinan, PhD
Professor of Epidemiology (Chronic Diseases)Cards
Additional Titles
Associate Cancer Center Director for Research Training and Education, Yale Cancer Center
Co-Director, Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, Yale School of Medicine
Co-Leader, Cancer Prevention and Control, Yale Cancer Center
Contact Info
Chronic Disease Epidemiology
PO Box 208034, 60 College St
New Haven, CT 06520
United States
Appointments
Additional Titles
Associate Cancer Center Director for Research Training and Education, Yale Cancer Center
Co-Director, Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, Yale School of Medicine
Co-Leader, Cancer Prevention and Control, Yale Cancer Center
Contact Info
Chronic Disease Epidemiology
PO Box 208034, 60 College St
New Haven, CT 06520
United States
Appointments
Additional Titles
Associate Cancer Center Director for Research Training and Education, Yale Cancer Center
Co-Director, Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, Yale School of Medicine
Co-Leader, Cancer Prevention and Control, Yale Cancer Center
Contact Info
Chronic Disease Epidemiology
PO Box 208034, 60 College St
New Haven, CT 06520
United States
Appointments
About
Copy Link
Titles
Professor of Epidemiology (Chronic Diseases)
Associate Cancer Center Director for Research Training and Education, Yale Cancer Center; Co-Director, Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, Yale School of Medicine; Co-Leader, Cancer Prevention and Control, Yale Cancer Center
Biography
Dr. Michaela Dinan is a Professor of Epidemiology in the Yale School of Public Health, Associate Cancer Center Director for Cancer Research Training and Education at the Yale Cancer Center (YCC) as well as Co-Director of the Yale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center. She is also co-leader of the YCC Cancer Prevention and Control Research Program. Dr. Dinan has extensive research expertise in leveraging existing real-world data sources as well as novel data linkages to examine oncology outcomes.
Dr. Dinan is a health services researcher by training and she specializes in using econometric and epidemiologic methodologies to analyze complex datasets. Specifically, Dr. Dinan's research examines advances in cancer care technologies, such as emerging treatments and diagnostics, and how these advances in technologies impact different cancer outcomes and experiences such as access, quality of care, cost of care, and health disparities.
Dr. Dinan has led studies funded by the National Institutes of Health, the American Cancer Society, and the Agency for Healthcare Research and Quality. She is currently MPI of an NCI-funded R01 study examining broad genomic profiling in patients with lung cancer to determine how testing and test results impact treatment, survival, and costs of care. Dr. Dinan is also leading a study funded by the ACS to develop and validate risk prediction algorithms to inform efficient and high-quality care for long-term cancer survivors.
In 2021, Dr. Dinan led the first linkage of the Medicare claims data to physical tumor specimens and cancer registry data. This proof-of-concept study was the first to demonstrate the ability to combine the detailed clinicopathologic data from the SEER Registry, the longitudinal follow-up provided by the Medicare claims data, with genomic sequence data obtained from the physical tumor specimen all into one dataset. Dr. Dinan is the PI of an ACS Research Scholar Grant building on this novel data linkage to determine the molecular etiology of aggressive screening-detected breast cancers.
Appointments
Chronic Disease Epidemiology
ProfessorPrimaryMedical Oncology and Hematology
Associate Professor on TermSecondary
Other Departments & Organizations
- Cancer Prevention and Control
- Chronic Disease Epidemiology
- COPPER Center
- Medical Oncology and Hematology
- Public Health Data Science and Data Equity
- Yale Cancer Center
- Yale School of Public Health
- YCC Collaborative Excellence
Education & Training
- PhD
- University of North Carolina, Health Policy and Management (2011)
Research
Copy Link
Overview
Dr. Dinan has extensive research expertise in leveraging existing real-world data sources as well as novel data linkages to examine oncology outcomes. She is a health services researcher with training in econometric and epidemiologic methodologies to analyze complex datasets. Specifically, Dr. Dinan's research involves issues related to access and quality of care, health disparities, and cost of care for cancer patients.
Medical Research Interests
Public Health Interests
ORCID
0000-0003-4849-4743
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Cary P Gross, MD
Michael S. Leapman, MD, MHS
Sarah Westvold, MPH
Shi-Yi Wang, MD, PhD
Xiaomei Ma, PhD
Ira Leeds, MD, MBA, FACS, FASCRS
Breast Neoplasms
Carcinoma, Renal Cell
Risk Assessment
Cancer Survivors
Costs and Cost Analysis
Chronic Disease
Publications
2026
Tumor characteristics associated with tomosynthesis versus digital mammography in older women with screen-detected breast cancer
Huang S, Westvold SJ, Soulos PR, Lewin JM, Zhan H, Lustberg MB, Greenup RA, Richman IB, Winer EP, Robinson TJ, Dinan MA. Tumor characteristics associated with tomosynthesis versus digital mammography in older women with screen-detected breast cancer. Breast Cancer Research And Treatment 2026, 218: 4. DOI: 10.1007/s10549-026-08013-4.Peer-Reviewed Original ResearchThis study investigates the benefits of digital breast tomosynthesis over conventional mammography in older women, showing limited advantage in detecting smaller tumors or invasive lobular carcinoma at age ≥75.Temporal trends and sociodemographic differences in influenza vaccination among U.S. cancer survivors, 2005-2024.
Conlin K, Mszar R, Ma Z, Cartmel B, Dinan M, Irwin M, Ferrucci L. Temporal trends and sociodemographic differences in influenza vaccination among U.S. cancer survivors, 2005-2024. Journal Of Clinical Oncology 2026, 44: 1674-1674. DOI: 10.1200/jco.2026.44.16_suppl.1674.Peer-Reviewed Original ResearchConceptsU.S. cancer survivorsAnnual percent changeHistory of cancerCancer survivorsSelf-reported historyVaccination prevalenceYoung survivorsSample of cancer survivorsNon-Hispanic white survivorsNational Health Interview SurveySurvey-weighted logistic regression modelsFactors associated with influenza vaccinationHealth Interview SurveyAnnual prevalence estimatesTemporal trendsInfluenza vaccinePrevalence of influenza vaccinationPublic health strategiesUptake of seasonal influenza vaccinationLogistic regression modelsHispanic survivorsWhite survivorsHealth strategiesInterview SurveySociodemographic differencesDifferences in the receipt of recommended cardiovascular assessment among cancer survivors in the United States by atherosclerotic cardiovascular disease status.
Mszar R, Alpert A, Gallardo-Vara E, Kang E, Conlin K, Barac A, Hull S, Baldassarre L, Dinan M, Irwin M, Ferrucci L. Differences in the receipt of recommended cardiovascular assessment among cancer survivors in the United States by atherosclerotic cardiovascular disease status. Journal Of Clinical Oncology 2026, 44: 12027-12027. DOI: 10.1200/jco.2026.44.16_suppl.12027.Peer-Reviewed Original ResearchConceptsCancer survivorsAtherosclerotic cardiovascular diseaseProportion of cancer survivorsNational Health Interview SurveyPre-existing atherosclerotic cardiovascular diseaseHealth Interview SurveyConfidence intervalsInitial cancer diagnosisNoninstitutionalized U.S. populationPast-yearCardiovascular disease statusMultivariate logistic regressionCancer survivorshipScreening ratesCross-sectional dataLevel of educationInterview SurveySociodemographic characteristicsSocioeconomic statusSuboptimal uptakeMultistage samplingOdds ratioCancer diagnosisSelf-ReportU.S. populationProstate-Specific Membrane Antigen Imaging and Initial Treatment for Prostate Cancer
Leapman M, Rothen J, Long J, Kim I, Mitchell A, Yu J, Dinan M, Gross C, Ma X. Prostate-Specific Membrane Antigen Imaging and Initial Treatment for Prostate Cancer. JAMA Oncology 2026, 12 PMID: 42096231, PMCID: PMC13154023, DOI: 10.1001/jamaoncol.2026.0893.Peer-Reviewed Original ResearchThis study investigates how PSMA-PET imaging for prostate cancer leads to earlier use of advanced therapies compared to traditional bone scans, impacting treatment decisions and costs.IP80-11 ASSOCIATION BETWEEN PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING AND INITIAL TREATMENT FOR PROSTATE CANCER AMONG COMMERCIAL INSURANCE BENEFICIARIES
Leapman M, Rothen J, Long J, Kim I, Mitchell A, Yu J, Dinan M, Gross C, Ma X. IP80-11 ASSOCIATION BETWEEN PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING AND INITIAL TREATMENT FOR PROSTATE CANCER AMONG COMMERCIAL INSURANCE BENEFICIARIES. Journal Of Urology 2026, 215: e1589. DOI: 10.1097/01.ju.0001191764.50307.1e.11.Peer-Reviewed Original ResearchMedicare Insurance Type and Broad Genomic Profiling in Metastatic Cancer
Chow R, Rothen J, Long J, Soulos P, Wang X, Mamtani R, Ma S, Kunst N, Dinan M, Gross C. Medicare Insurance Type and Broad Genomic Profiling in Metastatic Cancer. JAMA Network Open 2026, 9: e2614919. PMID: 42201732, PMCID: PMC13216988, DOI: 10.1001/jamanetworkopen.2026.14919.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsHospital referral regionsMedian odds ratioMedicare beneficiariesCohort studyMedicare AdvantagePayer typeMA beneficiariesOdds ratioStudy of Medicare beneficiariesCohort study of Medicare beneficiariesMedicare insurance typeMetastatic cancerLogistic regression modelsRetrospective cohort studyFFS beneficiariesReferral regionsMain OutcomesDiagnosis of metastatic cancerGenomic profilingGuideline recommendationsInsurance typeMedicarePrimary outcomeService recordsRegression modelsIP80-14 ASSOCIATION BETWEEN GENOMIC CLASSIFIER SCORES AND INITIAL MANAGEMENT OF LOCALIZED PROSTATE CANCER IN A POPULATION-BASED COHORT IN THE UNITED STATES
Leapman M, Wang R, Sprenkle P, Kim I, Dinan M, Gross C, Ma X. IP80-14 ASSOCIATION BETWEEN GENOMIC CLASSIFIER SCORES AND INITIAL MANAGEMENT OF LOCALIZED PROSTATE CANCER IN A POPULATION-BASED COHORT IN THE UNITED STATES. Journal Of Urology 2026, 215: e1590. DOI: 10.1097/01.ju.0001191764.50307.1e.14.Peer-Reviewed Original ResearchConceptsLessons Learned for Improving Trainee Engagement and Utilization of Education and Training Materials for Cancer Research
Santiago K, Galindo T, Dinan M. Lessons Learned for Improving Trainee Engagement and Utilization of Education and Training Materials for Cancer Research. Advances In Cancer Education And Quality Improvement 2026, 2: 10. PMID: 42180424, PMCID: PMC13193257, DOI: 10.52519/aceqi.26.2.1.a10.Peer-Reviewed Original ResearchConceptsCancer CenterNCI-designated Comprehensive Cancer CenterTrainees' awarenessComprehensive cancer centerYale Cancer CenterCentral repositoryUtilization of educationTrainee engagementSupport traineesEducation coordinatorsTraineesCancer researchConnection seriesEmailTraining materialsCareer enhancementEmail accountsLinkedIn pageMembership programsCancerTrainingCenterEngagementPracticeBidirectional communicationA Taxonomy for Assessing Real-World Targeted Cancer Therapy Options in the Context of Broad Genomic Profiling
Wang X, Long J, Rothen J, Huang S, Soulos P, Goldberg S, Robinson T, Ma S, Mamtani R, Presley C, Wang S, Kunst N, Gross C, Dinan M. A Taxonomy for Assessing Real-World Targeted Cancer Therapy Options in the Context of Broad Genomic Profiling. Journal Of The National Comprehensive Cancer Network 2026, 24: e257131. PMID: 41698347, PMCID: PMC13112471, DOI: 10.6004/jnccn.2025.7131.Peer-Reviewed Original ResearchThis study introduces Y-MATRIX, a taxonomy classifying genomic profiling results by clinical actionability, showing increased actionable findings in advanced lung cancer from 2017 to 2023.Adoption and Regional Variation of Prostate-Specific Membrane Antigen Positron Emission Tomography in the United States.
Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Spilberg G, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Rivera D, Kluetz P, Karnes R, Dinan M, Mitchell A, Kunst N, Wang S, Ma X, Gross C. Adoption and Regional Variation of Prostate-Specific Membrane Antigen Positron Emission Tomography in the United States. JCO Oncology Practice 2026, op2500617. PMID: 41632928, DOI: 10.1200/op-25-00617.Peer-Reviewed Original ResearchThis study investigates the rapid adoption of PSMA-PET imaging for prostate cancer in the U.S., highlighting increased usage since 2021 and disparities based on income and education.
News & Links
Copy Link
Media
News
- June 02, 2026
Ninth Annual YCC Trainee Research Colloquium Celebrates Outstanding Cancer Research
- February 10, 2026
Yale Cancer Center's CRTEC Hosts Cancer Research Discovery Program
- January 28, 2026
YCC Standout Research, Clinical Care, and Staff Support Recognized
- January 05, 2026
Aging & Cancer Research Joint Retreat
Get In Touch
Copy Link
Contacts
Chronic Disease Epidemiology
PO Box 208034, 60 College St
New Haven, CT 06520
United States
Locations
Ste 444
Academic Office
60 College Street
New Haven, CT 06510